Beckley Psytech will be presenting data on the effects of BPL-003 in patients with TRD who were also taking concomitant SSRIs in a poster presentation at the CNS Summit in Boston, United States from November 2 - 5. 

Breakthrough Therapy designation recognizes the potential of BPL-003 to deliver substantial improvement over existing therapies for patients with treatment-resistant depression. 

Beckley Psytech will be presenting data on BPL-003 in a poster presentation at the ECNP 2025 Congress in Amsterdam, The Netherlands. 

Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with treatment-resistant depression and demonstrated rapid, clinically meaningful and durable antidepressant effects, which are sustained for up to 3 months.

Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single dose

Beckley Psytech Ltd today announces that clinical and micro-phenomenology data from its Phase IIa study of BPL-003 for AUD will be presented at the 87th Annual Scientific Meeting of the US College on Problems of Drug Dependence (CPDD) from 14 - 18 June 2025 in New Orleans.

Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinic

It is with profound sadness that we acknowledge the passing of Lady Amanda Feilding, Founder and Director of the Beckley Foundation and Co-Founder of Beckley Psytech, aged 82.

Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and long-lasting antidepressant effect for up to three months after dosing. BPL-003 was well-tolerated and patients were able to be discharged within an average time of less than two hours. Data from the core, randomised stage of Beckley Psytech’s Phase IIb study of BPL-003 for treatment resistant depression is expected in mid-2025.

Beckley Psytech will be presenting data from Part 1 of its Phase IIa study of BPL-003 (NCT05660642) for Treatment Resistant Depression (TRD) at the Society of Biological Psychiatry’s (SOBP) Annual Meeting.